People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neuraptive Therapeutics, Inc. | — | Biotechnology | Series B | $29.8M | $295.3M | 2022 |
Ivan S Gergel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ivan S Gergel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Jackson | 1 | 4 |
| Gino DiSciullo | 1 | 4 |
| Ivan Gergel | 1 | 2 |
| Robert S Radie | 1 | 2 |
| David S Jackson | 1 | 1 |
| Evan S Tzanis | 1 | 1 |
| Greg Parekh | 1 | 1 |
| Randy Hubbell | 1 | 1 |
| David M Jackson | 1 | 1 |
| Randy S Hubbell | 1 | 1 |
| Greg S Parekh | 1 | 1 |
| David S Pierce | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.